CN1331469C - 一种苯酞类二聚体的用途 - Google Patents
一种苯酞类二聚体的用途 Download PDFInfo
- Publication number
- CN1331469C CN1331469C CNB2004100309897A CN200410030989A CN1331469C CN 1331469 C CN1331469 C CN 1331469C CN B2004100309897 A CNB2004100309897 A CN B2004100309897A CN 200410030989 A CN200410030989 A CN 200410030989A CN 1331469 C CN1331469 C CN 1331469C
- Authority
- CN
- China
- Prior art keywords
- cell
- adr
- drug
- tumor
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- WNZQDUSMALZDQF-UHFFFAOYSA-N 2-benzofuran-1(3H)-one Chemical compound C1=CC=C2C(=O)OCC2=C1 WNZQDUSMALZDQF-UHFFFAOYSA-N 0.000 title description 6
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 25
- 150000001875 compounds Chemical class 0.000 claims abstract description 22
- 230000036457 multidrug resistance Effects 0.000 claims abstract description 13
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 8
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 33
- 229960004528 vincristine Drugs 0.000 claims description 32
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 31
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 23
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 23
- 229960000975 daunorubicin Drugs 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 claims description 10
- 229930195573 Amycin Natural products 0.000 claims description 10
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 9
- 230000000259 anti-tumor effect Effects 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 43
- 230000000694 effects Effects 0.000 abstract description 18
- 210000004881 tumor cell Anatomy 0.000 abstract description 11
- 231100000331 toxic Toxicity 0.000 abstract description 6
- 230000002588 toxic effect Effects 0.000 abstract description 6
- 210000000987 immune system Anatomy 0.000 abstract description 2
- 210000000748 cardiovascular system Anatomy 0.000 abstract 1
- 125000005506 phthalide group Chemical class 0.000 abstract 1
- 230000005909 tumor killing Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 59
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 42
- 101001017818 Homo sapiens ATP-dependent translocase ABCB1 Proteins 0.000 description 41
- 229940079593 drug Drugs 0.000 description 26
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 206010059866 Drug resistance Diseases 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 238000007912 intraperitoneal administration Methods 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 5
- 241000233855 Orchidaceae Species 0.000 description 5
- 229940009456 adriamycin Drugs 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 230000008261 resistance mechanism Effects 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229960001722 verapamil Drugs 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 238000011275 oncology therapy Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000012313 reversal agent Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 description 2
- 101000823298 Homo sapiens Broad substrate specificity ATP-binding cassette transporter ABCG2 Proteins 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000000205 computational method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 125000002456 taxol group Chemical group 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 241000931705 Cicada Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 230000008265 DNA repair mechanism Effects 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000014842 Multidrug resistance proteins Human genes 0.000 description 1
- 108050005144 Multidrug resistance proteins Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101100400865 Mus musculus Abcb1b gene Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011208 chromatographic data Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 108700025647 major vault Proteins 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 231100000916 relative toxicity Toxicity 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
k562 | k562/adr | RF | kb | kbV200 | RF | |
ADR | 0.215±0.152 | 4.06±0.35 | 18.88 | 0.490 | 7.28 | 19.2 |
VCR | 0.018±0.01 | >20 | >1120 | 0.090 | >20 | >222 |
抗肿瘤药物 | |||
增敏剂 | ADR | VCR | DNR |
无VERLA | 2.288±0.2890.152±0.0210.189±0.015 | >>2019.48±0.35512.04±0.209 | 0.367±0.0160.075±0.0100.105±0.005 |
抗肿瘤药物 | |||
增敏剂 | ADR | VCR | DNR |
无VERLA | 1.970±0.1080.056±0.0190.040±0.013 | >209.171±0.5361.514±0.393 | 0.450±0.0630.028±0.004<0.01 |
RF(k562/adr) | RF(kbv200) | |||||
增敏剂 | ADR | VCR | DNR | ADR | VCR | DNR |
VERLA | 15.03212.122 | 1.0266>>1.661 | 4.89333.4952 | 35.17849.250 | 2.180713.210 | 16.07145.000 |
对照 | LA(5ug/ml) | LA(10ug/ml) | |
k562/adr | 79.8% | 76.7% | 77.8% |
kbv200 | 87.76% | 82.5% | 79.8% |
组别 | 瘤重(g) |
对照 | 0.958±0.324 |
VCR | 0.779±0.267 |
VCR+LA1(6ug/ml) | 0.631±0.174a |
VCR+LA2(10ug/ml) | 0.519±0.246b |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100309897A CN1331469C (zh) | 2004-04-05 | 2004-04-05 | 一种苯酞类二聚体的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100309897A CN1331469C (zh) | 2004-04-05 | 2004-04-05 | 一种苯酞类二聚体的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1679544A CN1679544A (zh) | 2005-10-12 |
CN1331469C true CN1331469C (zh) | 2007-08-15 |
Family
ID=35066567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100309897A Expired - Lifetime CN1331469C (zh) | 2004-04-05 | 2004-04-05 | 一种苯酞类二聚体的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1331469C (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2624150A1 (en) * | 2005-09-30 | 2007-04-05 | Fei Chen | The use of phthalide derivatives |
US8247444B2 (en) | 2007-01-19 | 2012-08-21 | Fei Chen | Anti-tumor effect of dimeric phthalide compound |
CN102772400A (zh) * | 2012-01-12 | 2012-11-14 | 上海中医药大学 | 欧当归内酯a的医药用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1059938A (ja) * | 1996-06-12 | 1998-03-03 | Ishihara Sangyo Kaisha Ltd | N−フェニルイミド系化合物又はその塩、それらの製造方法及びそれらを含有する医薬組成物 |
US5861518A (en) * | 1994-11-21 | 1999-01-19 | Dekker; Koenraad A. | Phthalide compounds and their production process |
CN1257706A (zh) * | 1998-12-18 | 2000-06-28 | 中国医学科学院药物研究所 | 丁基苯酞在制备抗血栓形成及抗血小板聚集药物中的应用 |
CN1375288A (zh) * | 2002-05-13 | 2002-10-23 | 周桂荣 | 一种治疗脑血管疾病的药物组合物 |
-
2004
- 2004-04-05 CN CNB2004100309897A patent/CN1331469C/zh not_active Expired - Lifetime
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5861518A (en) * | 1994-11-21 | 1999-01-19 | Dekker; Koenraad A. | Phthalide compounds and their production process |
JPH1059938A (ja) * | 1996-06-12 | 1998-03-03 | Ishihara Sangyo Kaisha Ltd | N−フェニルイミド系化合物又はその塩、それらの製造方法及びそれらを含有する医薬組成物 |
CN1257706A (zh) * | 1998-12-18 | 2000-06-28 | 中国医学科学院药物研究所 | 丁基苯酞在制备抗血栓形成及抗血小板聚集药物中的应用 |
CN1375288A (zh) * | 2002-05-13 | 2002-10-23 | 周桂荣 | 一种治疗脑血管疾病的药物组合物 |
Non-Patent Citations (4)
Title |
---|
Liquid chromatographic-electrospray mass spectrometric studyof the phthalides of Angelica sinensis and chemical changesof Z-ligustilide Long.Ze Lin et al,Journal of Chromatography A,Vol.810 1998 * |
Liquid chromatographic-electrospray mass spectrometric studyof the phthalides of Angelica sinensis and chemical changesof Z-ligustilide Long.Ze Lin et al,Journal of Chromatography A,Vol.810 1998;川芎化学成分研究 王文祥等,中草药,第33卷第1期 2002;天然3-羟基苯酞 徐霞等,中国医药工业杂志,第33卷第9期 2002 * |
天然3-羟基苯酞 徐霞等,中国医药工业杂志,第33卷第9期 2002 * |
川芎化学成分研究 王文祥等,中草药,第33卷第1期 2002 * |
Also Published As
Publication number | Publication date |
---|---|
CN1679544A (zh) | 2005-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lu et al. | Ganoderma lucidum extracts inhibit growth and induce actin polymerization in bladder cancer cells in vitro | |
CN103845314B (zh) | 一种丹参新酮在制备抗肿瘤药物中的应用 | |
CN103221373A (zh) | 用于治疗肺癌的方法和组合物 | |
CN1934101B (zh) | 脱氢苯基阿夕斯丁及其类似物以及脱氢苯基阿夕斯丁及其类似物的合成 | |
JP2021519745A (ja) | 腫瘍細胞の抗腫瘍薬に対する薬剤耐性を逆転させる方法および薬 | |
CN110433290A (zh) | 隐丹参酮和TKI抑制剂联用在制备Ph+急性淋巴细胞白血病化疗药物中的应用 | |
CN110054660A (zh) | 一种果糖修饰的乳腺癌靶向脂质材料的制备和应用 | |
He et al. | Water extract of sporoderm-broken spores of Ganoderma lucidum enhanced pd-l1 antibody efficiency through downregulation and relieved complications of pd-l1 monoclonal antibody | |
CN1331469C (zh) | 一种苯酞类二聚体的用途 | |
CN104370982B (zh) | 一类山荷叶素衍生物及其制备方法和用途 | |
CN101302199B (zh) | 桂德霉素及其在制备抗肿瘤药物中的应用 | |
CN102895523A (zh) | 一种山慈菇提取物的提取方法 | |
CN101732308B (zh) | 来普霉素b的新用途及含有它的药物组合物和产品 | |
CN110522923A (zh) | 果糖和rgd肽共修饰的双重靶向三阴性乳腺癌的脂质材料 | |
CN108379268A (zh) | 尼非韦罗在制备抗肿瘤药物中的应用 | |
CN108743577A (zh) | 一种抗他莫昔芬耐药乳腺癌的药物组合物 | |
CN104788391B (zh) | 肉桂酰中性红酰胺(ca‑pz)及其制备与应用 | |
CN104208073A (zh) | 原人参二醇在制备肿瘤多药耐药逆转剂中的用途 | |
CN102008715B (zh) | 抗肿瘤的MA-TNFα药物组合物及其应用 | |
CN103263409B (zh) | 双酮类化合物flbg-1108或者其药用盐在制备抗癌药物中的应用 | |
CN101843605A (zh) | 大黄素作为PI3K/Akt/mTOR信号转导通路活化分子p-Akt和p-mTOR的抑制剂及其应用 | |
CN114805117B (zh) | 抗肿瘤干细胞的紫草素及阿卡宁肟衍生物 | |
CN104666306A (zh) | 一种三萜类化合物在制备抗肿瘤药物中的应用 | |
CN102198139B (zh) | 具有抗肿瘤作用的药物组合物及其应用 | |
CN101933920A (zh) | 3,15-二羰基赤霉酸甲酯在逆转肿瘤多药耐药中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: SUZHOU MICRODIAG BIOMEDICINE Co.,Ltd. Assignor: Chen Fei|Wang Tao Contract record no.: 2010320000866 Denomination of invention: Use of dipolymer of phthalide Granted publication date: 20070815 License type: Exclusive License Open date: 20051012 Record date: 20100706 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20151123 Address after: 215123, 99 Jinji Avenue, Suzhou Industrial Park, Jiangsu, Suzhou, 16 North West District Patentee after: PUSHI HUAKANG JIANGSU MEDICAL TECHNOLOGY Co.,Ltd. Address before: 310027, Zhejiang, Hangzhou, Xinhua Road, Temple of water and land Lane 3-3-601 Patentee before: Wang Tao Patentee before: Chen Fei |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211125 Address after: 215127 rooms 201 and 301, C4 building, biological nano Park, 218 Xinghu street, Suzhou Industrial Park, Suzhou, Jiangsu Province Patentee after: JIANGSU MICRODIAG BIOMEDICINE TECHNOLOGY Co.,Ltd. Address before: 215123 building 16, Northwest District, Suzhou nano City, No. 99, Jinji Avenue, Suzhou Industrial Park, Jiangsu Province Patentee before: PUSHI HUAKANG JIANGSU MEDICAL TECHNOLOGY Co.,Ltd. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20070815 |